These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39157745)

  • 1. Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report.
    Zhang Y; Hou G; Zhang L; Li S
    Infect Drug Resist; 2024; 17():3501-3506. PubMed ID: 39157745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraventricular Plus Systemic Antibiotic Therapy for Treating Polymyxin-Resistant
    Wang H; Zhou Q; Huang K; Yang X; Wen L
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac084. PubMed ID: 35355891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
    Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
    Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical efficacy and drug resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant gram-negative bacilli infection.
    Xiao S; Fu Q; Miao Y; Zhao M; Lu S; Xu J; Zhao W
    Front Microbiol; 2023; 14():1198926. PubMed ID: 37664109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
    Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
    Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.
    Gu J; Xu J; Zuo TT; Chen YB
    J Glob Antimicrob Resist; 2021 Sep; 26():20-25. PubMed ID: 34020072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant
    Ahmed F; Abraham B; Kamal Saeed N; Mohamed Naser H; Sridharan K
    Crit Care Res Pract; 2024; 2024():3427972. PubMed ID: 38868174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
    Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
    Infection; 2024 Jun; ():. PubMed ID: 38884857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
    Karampatakis T; Tsergouli K; Lowrie K
    Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
    Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
    Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
    Qu J; Xu J; Liu Y; Hu C; Zhong C; Lv X
    Int J Antimicrob Agents; 2023 Aug; 62(2):106872. PubMed ID: 37247645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae.
    Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC
    J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant
    Feldman S; Russo A; Ceccarelli G; Borrazzo C; Madge C; Venditti M; Merli M
    J Clin Exp Hepatol; 2022; 12(5):1293-1300. PubMed ID: 36157152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of ventriculitis caused by
    Gofman N; To K; Whitman M; Garcia-Morales E
    Am J Health Syst Pharm; 2018 Jul; 75(13):953-957. PubMed ID: 29941534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant
    Li D; Liao W; Huang HH; Du FL; Wei DD; Mei YF; Long D; Wan LG; Liu Y; Zhang W
    Infect Drug Resist; 2020; 13():2673-2680. PubMed ID: 32821131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study.
    Hu Y; Li D; Zhang G; Dai Y; Chen M; Jiang H; Cui W
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):875-884. PubMed ID: 38443737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Zhao X; Li S; Zhang Y; Wang J; Wang C; Qin X; Hu F; Wang M
    Int J Antimicrob Agents; 2023 May; 61(5):106777. PubMed ID: 36905946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant
    Chen J; Liang Q; Chen X; Wu J; Wu Y; Teng G; Huang M
    Infect Drug Resist; 2022; 15():655-667. PubMed ID: 35241917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.